204 related articles for article (PubMed ID: 28148549)
1. Risk of cumulative toxicity after complete melanoma response with pembrolizumab.
Hsieh AH; Faithfull S; Brown MP
BMJ Case Rep; 2017 Feb; 2017():. PubMed ID: 28148549
[TBL] [Abstract][Full Text] [Related]
2. Limbic encephalitis following immunotherapy against metastatic malignant melanoma.
Salam S; Lavin T; Turan A
BMJ Case Rep; 2016 Mar; 2016():. PubMed ID: 27009198
[TBL] [Abstract][Full Text] [Related]
3. Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.
Robert C; Ribas A; Hamid O; Daud A; Wolchok JD; Joshua AM; Hwu WJ; Weber JS; Gangadhar TC; Joseph RW; Dronca R; Patnaik A; Zarour H; Kefford R; Hersey P; Zhang J; Anderson J; Diede SJ; Ebbinghaus S; Hodi FS
J Clin Oncol; 2018 Jun; 36(17):1668-1674. PubMed ID: 29283791
[TBL] [Abstract][Full Text] [Related]
4. A Rare Case of Pembrolizumab-Induced Uveitis in a Patient with Metastatic Melanoma.
Hanna KS
Pharmacotherapy; 2016 Nov; 36(11):e183-e188. PubMed ID: 27716999
[TBL] [Abstract][Full Text] [Related]
5. Autoimmune limbic encephalitis with anti-contactin-associated protein-like 2 antibody secondary to pembrolizumab therapy.
Brown MP; Hissaria P; Hsieh AH; Kneebone C; Vallat W
J Neuroimmunol; 2017 Apr; 305():16-18. PubMed ID: 28284337
[TBL] [Abstract][Full Text] [Related]
6. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
Long GV; Atkinson V; Cebon JS; Jameson MB; Fitzharris BM; McNeil CM; Hill AG; Ribas A; Atkins MB; Thompson JA; Hwu WJ; Hodi FS; Menzies AM; Guminski AD; Kefford R; Kong BY; Tamjid B; Srivastava A; Lomax AJ; Islam M; Shu X; Ebbinghaus S; Ibrahim N; Carlino MS
Lancet Oncol; 2017 Sep; 18(9):1202-1210. PubMed ID: 28729151
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma.
Ivashko IN; Kolesar JM
Am J Health Syst Pharm; 2016 Feb; 73(4):193-201. PubMed ID: 26843495
[TBL] [Abstract][Full Text] [Related]
8. Safety of pembrolizumab for the treatment of melanoma.
Martin-Liberal J; Kordbacheh T; Larkin J
Expert Opin Drug Saf; 2015 Jun; 14(6):957-64. PubMed ID: 25927979
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab-induced dermatomyositis in a patient with metastatic melanoma.
Berger M; Legeay AL; Souci S; Streichenberger N; Thomas L; Dalle S
Eur J Cancer; 2018 Nov; 104():227-230. PubMed ID: 30322679
[No Abstract] [Full Text] [Related]
10. Delayed skin toxicity associated with pembrolizumab therapy for metastatic melanoma.
Arianayagam S; Ieremia E; Matin RN
Eur J Dermatol; 2019 Jun; 29(3):349-351. PubMed ID: 31389799
[No Abstract] [Full Text] [Related]
11. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.
Robert C; Ribas A; Wolchok JD; Hodi FS; Hamid O; Kefford R; Weber JS; Joshua AM; Hwu WJ; Gangadhar TC; Patnaik A; Dronca R; Zarour H; Joseph RW; Boasberg P; Chmielowski B; Mateus C; Postow MA; Gergich K; Elassaiss-Schaap J; Li XN; Iannone R; Ebbinghaus SW; Kang SP; Daud A
Lancet; 2014 Sep; 384(9948):1109-17. PubMed ID: 25034862
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Robert C; Schachter J; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank CU; Hamid O; Mateus C; Shapira-Frommer R; Kosh M; Zhou H; Ibrahim N; Ebbinghaus S; Ribas A;
N Engl J Med; 2015 Jun; 372(26):2521-32. PubMed ID: 25891173
[TBL] [Abstract][Full Text] [Related]
13. Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma.
Kirchberger MC; Hauschild A; Schuler G; Heinzerling L
Eur J Cancer; 2016 Sep; 65():182-4. PubMed ID: 27501507
[TBL] [Abstract][Full Text] [Related]
14. Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma.
Parakh S; Nguyen R; Opie JM; Andrews MC
Australas J Dermatol; 2017 Aug; 58(3):e109-e112. PubMed ID: 27170423
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: a report of three cases.
Blakeway EA; Elshimy N; Muinonen-Martin A; Marples M; Mathew B; Mitra A
Melanoma Res; 2019 Jun; 29(3):338-341. PubMed ID: 30762712
[TBL] [Abstract][Full Text] [Related]
16. Eosinophilic Fasciitis and Acute Encephalopathy Toxicity from Pembrolizumab Treatment of a Patient with Metastatic Melanoma.
Khoja L; Maurice C; Chappell M; MacMillan L; Al-Habeeb AS; Al-Faraidy N; Butler MO; Rogalla P; Mason W; Joshua AM; Hogg D
Cancer Immunol Res; 2016 Mar; 4(3):175-8. PubMed ID: 26822024
[TBL] [Abstract][Full Text] [Related]
17. Progression of Hypopituitarism and Hypothyroidism after Treatment with Pembrolizumab in a Patient with Adrenal Metastasis from Non-small-cell Lung Cancer.
Yamagata S; Kageyama K; Takayasu S; Asari Y; Makita K; Terui K; Daimon M
Intern Med; 2019 Dec; 58(24):3557-3562. PubMed ID: 31462588
[TBL] [Abstract][Full Text] [Related]
18. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
Ribas A; Hamid O; Daud A; Hodi FS; Wolchok JD; Kefford R; Joshua AM; Patnaik A; Hwu WJ; Weber JS; Gangadhar TC; Hersey P; Dronca R; Joseph RW; Zarour H; Chmielowski B; Lawrence DP; Algazi A; Rizvi NA; Hoffner B; Mateus C; Gergich K; Lindia JA; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Robert C
JAMA; 2016 Apr; 315(15):1600-9. PubMed ID: 27092830
[TBL] [Abstract][Full Text] [Related]
19. Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy.
Shao K; McGettigan S; Elenitsas R; Chu EY
J Cutan Pathol; 2018 Jan; 45(1):74-77. PubMed ID: 29028121
[TBL] [Abstract][Full Text] [Related]
20. Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab.
Lau KH; Kumar A; Yang IH; Nowak RJ
Muscle Nerve; 2016 Jun; 54(1):157-61. PubMed ID: 27065302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
